Pharmaceuticals, Biotechnology and Life Sciences
The new Oasmia board, led by Jörgen Olsson who was elected as the Chairman, independent Board member and former CEO of Hoist Finance, will review the business and proceedings of Oasmia in several aspects.
BOSTON–(BUSINESS WIRE)–Gelesis, a biotechnology company developing first-in-class mechanotherapeutics to treat obesity and other chronic diseases related to the gastrointestinal (GI)…
Minneapolis, Chicago and Cleveland lead the pack in investment, while the number of Midwest companies receiving funding increases 20% CLEVELAND–(BUSINESS…
WATERTOWN, Mass.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/CEO?src=hash" target="_blank"gt;#CEOlt;/agt;–FORMA Therapeutics announced today the appointment of Frank D. Lee as Chief Executive Officer, starting on…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced that interim…
ALAMEDA, Calif.–(BUSINESS WIRE)–AgeX Therapeutics, Inc. (NYSE American: AGE), a biotechnology company focused on innovative therapeutics for human aging, announced today…
SAN DIEGO–(BUSINESS WIRE)–CB Therapeutics is an innovative biotechnology company focusing on research and production of cannabinoids. The company utilizes its…
German Merck, which operates its biopharmaceutical business as EMD Serono in the US and Canada, and Pfizer are dropping the Phase III JAVELIN Ovarian PARP 100 study in which they tested avelumab combined with chemotherapy followed by maintenance therapy of avelumab in combination with talazoparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, versus an active comparator in treatment-naïve patients with locally advanced or metastatic ovarian cancer (Stage III or Stage IV), as they described in the press release on Wednesday.
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather…
STERLING, Kan.–(BUSINESS WIRE)–Genzada Pharmaceuticals USA Inc. (Genzada), a subsidiary of Ionics Life Sciences Limited, announced today that the first patient…